Filter byLast updatedSelectAfterBeforeFrom - ToDateEnd DateCategoryHumanCorporateTopicCOVID-19MedicinesReferralsAdvanced therapiesAntimicrobial resistanceBiologicalsBiosimilarsBrexitCareersClinical trialsCompassionate useCompliance and inspectionsCorporateData on medicinesEarly accessFeesGeneric and hybrid medicinesGovernanceInnovationMaximum residue limitMedication errorMedicines for use outside the EUMedicine shortagesMpoxPaediatricsParallel distributionPharmacovigilanceProcurementProduct informationQuality of medicinesRare diseasesRegulatory and procedural guidanceResearch and developmentScientific adviceScientific guidelinesSMEVaccinesVeterinary limited marketsDiseases areaViral diseasesCancerDiabetesImmune-system diseasesCardiovascular diseasesHIV and AIDSNeurodegenerative diseasesTreatment of human immunodeficiency virus type 1 (HIV-1) infectionResponsible bodyCHMPManagement BoardCATCMDhCOMPCVMPHMPCPDCOPRACPatient safetyYesFiltersResults (9) KineretSort byLast update date (new to old)Last update date (old to new)A-ZZ-AEMA Management Board: highlights of December 2021 meeting17 December 2021NewsCorporateMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 202117 December 2021NewsHumanCOVID-19MedicinesEMA recommends approval for use of Kineret in adults with COVID-1916 December 2021NewsHumanCOVID-19EMA starts evaluating the use of Kineret in adult COVID-19 patients at increased risk of severe respiratory failure19 July 2021NewsHumanCOVID-19MedicinesMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated)27 March 2020NewsHumanMedicinesReferralsMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 201823 February 2018NewsHumanNew treatment option for rare inflammatory disease23 February 2018Press releaseHumanMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 201320 September 2013NewsHumanPublic statement on the increased risk of serious infection and neutropenia in patients treated concurrently with Kineret (anakinra) and Enbrel (etanercept)5 February 2003News
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 202117 December 2021NewsHumanCOVID-19Medicines
EMA starts evaluating the use of Kineret in adult COVID-19 patients at increased risk of severe respiratory failure19 July 2021NewsHumanCOVID-19Medicines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated)27 March 2020NewsHumanMedicinesReferrals
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 201823 February 2018NewsHuman
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 201320 September 2013NewsHuman
Public statement on the increased risk of serious infection and neutropenia in patients treated concurrently with Kineret (anakinra) and Enbrel (etanercept)5 February 2003News